Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion Post ContentalnyRead More You might also be interested in reading Bitcoin Price Rebounds, But Could the Downtrend Return?. February 14, 2025 In Mainstream ← Previous post Next post →